Haven Manufacturing Acquired by CORE Industrial Partners Portfolio Company CGI Automated Manufacturing

Haven Manufacturing acquired: CORE Industrial Partners (“CORE”), a Chicago-based private equity firm, announced today the acquisition of Haven Manufacturing (“Haven” or the “Company”), a full-service contract manufacturer of highly engineered components, by CORE portfolio company CGI Automated Manufacturing (“CGI”).

Haven Manufacturing is the fourth add-on acquisition to the CGI platform launched by CORE in August 2021.

Specializing in components for medical devices, medical equipment, and related applications, Haven provides a full suite of manufacturing services, including design assistance, prototyping, EDM, waterjet, laser etching, blasting, grinding, and passivation, as well as broad CNC machining capabilities to supply precision parts in lengths from less than one inch up to 85 inches. The Company’s metrology division augments its medical products manufacturing focus, providing contract measurement services for the medical, aerospace & defense, industrial, and consumer end markets.

Founded in 1966, Haven operates two facilities with more than 60,000 total square feet in Grand Haven, Michigan, and Ossian, Indiana. The Company holds ISO 13485, ISO 9001, and ISO 17025 certifications and is both FDA-registered and ITAR-compliant.

TJ Chung, the Senior Partner of CORE and Chairman of CGI, said, “Haven is strategically located to serve leading medical device and equipment manufacturers in Northeast Indiana and Southwest Michigan. The Company’s deep experience in the medical end market fits extremely well with CGI’s focus on serving attractive, growing industries requiring tight tolerances for mission-critical applications.”

Len Feddema, President of Haven Manufacturing, said, “My partners and I believe in the fundamental element of teamwork, with pride and respect for our employees and customers. We believe the quality of the entire team and its involvement in problem-solving has been and continues to be, the crucial component to our success. In collaboration with CGI and CORE, we’re excited to expand beyond Haven to even better serve our valued customers.”

Winston & Strawn LLP provided legal representation to CGI and CORE in the transaction.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.